Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(146 produtos)
- Bcr-Abl(102 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(79 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(268 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1431 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Cor e Forma:SolidPeso molecular:327.33GZD856
CAS:<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Fórmula:C29H27F3N6OPureza:98%Cor e Forma:SolidPeso molecular:532.56XST-14
CAS:<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Fórmula:C16H21NO4Pureza:99.84% - 99.84%Cor e Forma:SolidPeso molecular:291.34VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Fórmula:C26H20Cl2F3N5O3S2Cor e Forma:SolidPeso molecular:642.5NVP-AAD777
CAS:<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Fórmula:C22H14F6N4Pureza:98%Cor e Forma:SolidPeso molecular:448.36ALK5-IN-29
CAS:<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Fórmula:C24H25FN8Cor e Forma:SolidPeso molecular:444.51Adhesamine
CAS:<p>Adhesamine, a dumbbell molecule, enhances cell adhesion, growth, neuron differentiation, and survival via MAPK/FAK.</p>Fórmula:C24H32Cl4N8O2S2Cor e Forma:SolidPeso molecular:670.51JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SCor e Forma:SolidPeso molecular:393.46EGFR/HER2/TS-IN-2
CAS:<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Fórmula:C26H21N7OS2Cor e Forma:SolidPeso molecular:511.62BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Cor e Forma:SolidPeso molecular:485.6VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Fórmula:C26H21ClF3N5O3S2Cor e Forma:SolidPeso molecular:608.05FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Fórmula:C21H23F3N6OCor e Forma:SolidPeso molecular:432.44Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Cor e Forma:SolidPeso molecular:292.25INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Cor e Forma:SolidPeso molecular:380.23PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Fórmula:C26H29Cl2N5O3Pureza:97.01%Cor e Forma:SolidPeso molecular:530.45MAX-40279 hydrochloride
CAS:<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Fórmula:C22H24ClFN6OSCor e Forma:SolidPeso molecular:474.98E-4177
CAS:<p>E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.</p>Fórmula:C24H21N3O2Pureza:98.67% - 99.57%Cor e Forma:SolidPeso molecular:383.44Con B-1
CAS:<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Fórmula:C38H52ClN7O6SCor e Forma:SolidPeso molecular:770.38MG-262
CAS:<p>MG-262 is a reversible proteasome inhibitor with multiple biological activities [1] [2] [3].</p>Fórmula:C25H42BN3O6Cor e Forma:SolidPeso molecular:491.43PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Cor e Forma:SolidPeso molecular:538.56MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SCor e Forma:SolidPeso molecular:1056.72BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Cor e Forma:SolidPeso molecular:460.761,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Cor e Forma:SolidPeso molecular:557.54BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Fórmula:C18H12F3N3O2Cor e Forma:SolidPeso molecular:359.3Cenisertib
CAS:<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Fórmula:C24H30FN7OCor e Forma:SolidPeso molecular:451.54MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Cor e Forma:SolidPeso molecular:346.38EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Cor e Forma:SolidPeso molecular:451.56MAX-40279
CAS:<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Fórmula:C22H23FN6OSCor e Forma:SolidPeso molecular:438.52EGFR/HER2/TS-IN-1
CAS:<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Fórmula:C24H15N5O4S2Cor e Forma:SolidPeso molecular:501.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Cor e Forma:SolidPeso molecular:537.65Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Cor e Forma:SolidPeso molecular:401.46AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Fórmula:C19H14F3N3O2Cor e Forma:SolidPeso molecular:373.33VEGFR-2-IN-23
CAS:<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Fórmula:C22H15N5O2Cor e Forma:SolidPeso molecular:381.39BI1002494
CAS:<p>BI1002494 is an effective and selective Syk inhibitor.</p>Fórmula:C23H25N3O5Pureza:98%Cor e Forma:SolidPeso molecular:423.46CHMFL-ABL/KIT-155
CAS:<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Fórmula:C33H38F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:609.68EGFR-IN-51
CAS:<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Fórmula:C21H15N3O2SCor e Forma:SolidPeso molecular:373.43Lck-IN-1
CAS:<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Fórmula:C14H15N5Cor e Forma:SolidPeso molecular:253.3Glufanide disodium
CAS:<p>Glufanide disodium is an immunomodulator.</p>Fórmula:C16H17N3O5Na2Cor e Forma:SolidPeso molecular:377.3AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Fórmula:C15H12N4SCor e Forma:SolidPeso molecular:280.35AG1433
CAS:<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Fórmula:C16H15ClN2O2Cor e Forma:SolidPeso molecular:302.76α7 nAchR-JAK2-STAT3 agonist 1
CAS:<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Fórmula:C25H30O6Cor e Forma:SolidPeso molecular:426.5Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Fórmula:C27H52BrN8O3PPureza:98%Cor e Forma:SolidPeso molecular:647.644EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Cor e Forma:SolidPeso molecular:224.34FIIN-4
CAS:<p>FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.</p>Fórmula:C35H38N8O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:634.73BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Fórmula:C25H21Cl2N5O2Cor e Forma:SolidPeso molecular:494.37Luxeptinib
CAS:<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Fórmula:C25H17F4N5O2Cor e Forma:SolidPeso molecular:495.43WY-135
CAS:<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Fórmula:C28H34ClN9O3SPureza:98%Cor e Forma:SolidPeso molecular:612.15GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Cor e Forma:SolidPeso molecular:489.86FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Cor e Forma:SolidPeso molecular:455.94THS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Fórmula:C11H12F3N3O3Pureza:99.89%Cor e Forma:SolidPeso molecular:291.23CP-547632 hydrochloride
CAS:<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Fórmula:C20H25BrClF2N5O3SCor e Forma:SolidPeso molecular:568.86PHA-680626
CAS:<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Fórmula:C23H26N6O2SCor e Forma:SolidPeso molecular:450.56VEGFR-2-IN-27
CAS:<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Fórmula:C25H21FN4O4Cor e Forma:SolidPeso molecular:460.46WDR5-IN-4
CAS:<p>WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.</p>Fórmula:C25H22Cl2FN5OPureza:98%Cor e Forma:SolidPeso molecular:498.38EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SCor e Forma:SolidPeso molecular:434.31Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Fórmula:C37H35F2N5O9SPureza:98%Cor e Forma:SolidPeso molecular:763.76BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Fórmula:C26H26N6O2Cor e Forma:SolidPeso molecular:454.52BIIB-057
CAS:<p>BIIB-057 is a selective Syk inhibitor.</p>Fórmula:C19H23N9OPureza:98%Cor e Forma:SolidPeso molecular:393.45Ibrutinib-MPEA
CAS:<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Fórmula:C32H39N9O2Cor e Forma:SolidPeso molecular:581.71Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Cor e Forma:SolidPeso molecular:408.5Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Cor e Forma:SolidPeso molecular:462.9EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Cor e Forma:SolidPeso molecular:538.64pan-HER-IN-2
CAS:<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Fórmula:C19H15BrClN5OCor e Forma:SolidPeso molecular:444.71EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Fórmula:C28H30N4O3Cor e Forma:SolidPeso molecular:470.56PF-00337210
CAS:<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Fórmula:C26H27N3O5Cor e Forma:SolidPeso molecular:461.51VEGFR-2-IN-20
CAS:<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Fórmula:C20H20N4O3SCor e Forma:SolidPeso molecular:396.46Depatuxizumab mafodotin
CAS:<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Cor e Forma:LiquidPDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Fórmula:C26H39N9Cor e Forma:SolidPeso molecular:477.65ALK2-IN-5
CAS:<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Fórmula:C24H32N8O2Cor e Forma:SolidPeso molecular:464.56OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Cor e Forma:SolidPeso molecular:542.55SB-633825
CAS:<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Fórmula:C28H25N3O3SPureza:98%Cor e Forma:SolidPeso molecular:483.58Syk-IN-1
CAS:<p>Syk-IN-11 is a selective Syk inhibitor.</p>Fórmula:C18H22N8OCor e Forma:SolidPeso molecular:366.42CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Fórmula:C28H26F3N7O2Cor e Forma:SolidPeso molecular:549.55LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Fórmula:C27H42N4O2Pureza:98%Cor e Forma:SolidPeso molecular:454.65EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Fórmula:C25H25ClFN5O4Cor e Forma:SolidPeso molecular:513.95TG 100572
CAS:<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Fórmula:C26H26ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:475.97Ebselen oxide
CAS:<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Fórmula:C13H9NO2SePureza:98%Cor e Forma:SolidPeso molecular:290.18PD 166326
CAS:<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Fórmula:C21H16Cl2N4O2Cor e Forma:SolidPeso molecular:427.28SMU-B
CAS:<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Fórmula:C26H25Cl2FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:515.41T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Fórmula:C30H25ClFN5O4Cor e Forma:SolidPeso molecular:574BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Fórmula:C27H28N6O2Cor e Forma:SolidPeso molecular:468.55JAK3/BTK-IN-5
CAS:<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Fórmula:C19H22ClN7O2Cor e Forma:SolidPeso molecular:415.88EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Fórmula:C19H12BrClO2Cor e Forma:SolidPeso molecular:387.65Ficonalkib
CAS:<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Fórmula:C29H39N7O3SCor e Forma:SolidPeso molecular:565.73GW768505A free base
CAS:<p>GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.</p>Fórmula:C27H19F4N5O3Cor e Forma:SolidPeso molecular:537.47OD36
CAS:<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Fórmula:C16H15ClN4O2Pureza:99.89%Cor e Forma:SolidPeso molecular:330.77GDC-0834 Racemate
CAS:<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Fórmula:C33H36N6O3SCor e Forma:SolidPeso molecular:596.74EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Cor e Forma:SolidPeso molecular:496.56NSC-689857
CAS:<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Fórmula:C25H29NO4Pureza:98%Cor e Forma:SolidPeso molecular:407.5TX-1123
CAS:<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Fórmula:C20H24O3Cor e Forma:SolidPeso molecular:312.4MAX-40279 hemiadipate
CAS:<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Fórmula:C50H56F2N12O6S2Cor e Forma:SolidPeso molecular:1023.19(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Cor e Forma:SolidPeso molecular:485.94AZM475271
CAS:<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Fórmula:C23H27ClN4O3Pureza:99.78%Cor e Forma:SolidPeso molecular:442.94R916562
CAS:<p>R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.</p>Fórmula:C26H30ClN9SPureza:98%Cor e Forma:SolidPeso molecular:536.09ULK1-IN-2
CAS:<p>ULK1-IN-2, a potent anticancer agent, inhibits ULK1, induces apoptosis, blocks autophagy, and shows high cytotoxicity with an IC50 of 1.94 μM in A549 cells.</p>Fórmula:C19H16BrFN4O6Pureza:99.25% - 99.25%Cor e Forma:SolidPeso molecular:495.26ENMD-1198
CAS:<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>Fórmula:C20H25NO2Pureza:98%Cor e Forma:SolidPeso molecular:311.42FAK-IN-8
CAS:<p>FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].</p>Fórmula:C15H9Cl2N3O2SCor e Forma:SolidPeso molecular:366.22PHM16
CAS:<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Fórmula:C20H22N6O4Pureza:98%Cor e Forma:SolidPeso molecular:410.43BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Fórmula:C26H24N10O2Cor e Forma:SolidPeso molecular:508.53TC-S 7003
CAS:TC-S 7003 (Lck Inhibitor) is a Lck inhibitor with anti-inflammatory activity that inhibits T-cell proliferation and can be used to study arthritis.Fórmula:C31H30N8OPureza:99.74%Cor e Forma:SolidPeso molecular:530.62
